Key facts
- This page summarizes SINO LION VENTURES Ltd's Form 3 filing for Indaptus Therapeutics, Inc. (INDP).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Apr 2026, 19:16.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
On March 19, 2026, Sino Lion Ventures Limited (the "Reporting Person"), the other purchasers named therein and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired an aggregate of 259,300 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock"). Each share of Series AAA Preferred Stock is convertible into 150 shares of the Issuer's common stock, $0.01 par value per share (the "Common Stock"). Following the closing of such transaction on March 23, 2026, the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock held by the Reporting Person, resulting in the issuance of an aggregate of 38,895,000 shares of Common Stock.
Footnote F2
The reported securities may also be deemed to be beneficially owned by Chenhao Xu, whom disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in such shares, if any.